NAD(P)H:Quinone Oxidoreductase 1 Expression in Human Reproductive System and Mitomycin-C Cytotoxicity: A New Chapter for Old Compounds?

Francesco Zappa*, Timothy Ward, Ennio Pedrinis, John Butler and Alan McGown
CRC Department of Drug Development, Paterson Institute for Cancer Research and Christie Hospital NHS Trust (F.Z., T.W., J.B., A.McG.), Manchester, UK and Institute of Pathology of Southern Switzerland (E.P.), Locarno, Switzerland

Abstract

NAD(P)H:quinone oxidoreductase 1 (NQO1; DT-diaphorase; DTD) is a cytosolic two-electron reductase, and compounds of the family of quinones such as mitomycin C are efficiently bio-activated by this enzyme. The observation that DT-diaphorase is over-expressed in many cancerous tissues compared to normal tissues has provided us with a selective target that can be exploited in the design of novel anticancer agents. Because information about the cell-specific expression of DT-diaphorase was so scarce, this study was initiated to map the distribution of this enzyme in human tissues. We report here our findings concerning the reproductive organs.

Tissue samples taken from various components of the human reproductive system were analysed for expression of DT-diaphorase by immunohistochemistry. We found a strong expression of this enzyme in testicular stromal cells (Leydig’s cells) and in the epithelium of the epididymis and Fallopian tube.

These results suggest that quinones bio-activated by DT-diaphorase may be toxic to the reproductive system and cause clinical problems due to testosterone deficiency in men and infertility in both sexes. The implications of these observations need to be considered in pre-clinical evaluation of new anticancer quinones and in patients treated with these compounds.

Keywords: DT-diaphorase; NQO1; Cancer; Mitomycin toxicity; Quinones; immunohistochemistry; Infertility-male etiology; Infertility-female etiology; Reproductive system

Introduction

Alkylating agents have been used in cancer chemotherapy for over 50 years [1] and are still among the most widely administered and effective anti-tumour drugs. They are reactive chemicals that form covalent bonds with a variety of chemical groups on essential cellular molecules, but their reaction with DNA appears to be the primary event that causes cell death. These compounds are most toxic towards rapidly dividing cells, and side effects are therefore predicted to be against the bone marrow, gastrointestinal mucosa, hair follicles and seminiferous tubules [2]. Quinones are a distinct class of alkylating agents that need to be activated by metabolic reduction [3]. The same side effects have been described for mitomycin C as for other alkylating agents except gonadal toxicity. In fact, no evidence has been presented for a possible toxicity of anticancer quinones on the reproductive system. Mitomycin C, the prototype of this group, requires enzymatic activation by reduction of the quinone group; this activation is NADPH-dependent and when activated, mitomycin produces cross-links in DNA. The specificity of agents of this type against tumour cells depends on the activity of the bio-reductive enzyme DT-diaphorase (NQO1; NAD(P)H:quinone oxidoreductase 1; DTD). DTD-rich cells have been shown to be more sensitive [4-6] to these agents. DT-diaphorase over-expression has been demonstrated in many cancerous tissues compared to normal tissues [7,8]. This allows the generation of higher concentrations of reactive compounds at the tumour site by the utilisation of DTD-activated pro-drugs. Compounds such as mitomycin C, streptonigrin, MeDZQ, EOg, tirapazamine and RH1 are efficiently bioactivated by this enzyme [4,5,9-15]. RH1 is the compound selected for clinical development by the Cancer Research Campaign (CRC) and the NCI, and after its preclinical evaluation [16], it successfully underwent phase 1 evaluation [17].

Physiologically, DT-diaphorase is believed to protect normal cells against redox cycling and oxidative stress by the reductive detoxification of quinones and their derivatives.

Quinones such as mitomycin C and streptonigrin have been used for 40 years and are active against head and neck, breast, gastrointestinal and lung cancers. Despite the introduction of new families of antitumour drugs, mitomycin C is still widely used. It is suggested that the antitumour activity of such compounds could be enhanced by selective induction of DT-diaphorase in tumour cells compared to normal cells [18,19]; DTD can also be induced by dietary compounds [20]. A polymorphism of the gene encoding this enzyme has been described [21,22], and this variant is associated with reduced DT-diaphorase activity and resistance to anticancer agents requiring bio-reductive activation [23].

Despite the widespread interest in this enzyme because of its potential for selectively activating anticancer pro-drugs in tumour cells, which decreases the risk of toxicity to normal cells, very little information is available about its physiological distribution in the human body.

*Corresponding author: Francesco Zappa, Department Of Medical Oncology, Clinica Luganese, 6903 Lugano, Switzerland, Tel: +41 91 960 8147; Fax: +41 91 960 8580; E-mail: Francesco.zappa@clinicaluganese.ch

Received December 03, 2013; Accepted December 24, 2013; Published December 26, 2013

Citation: Zappa F, Ward T, Pedrinis E, Butler J, McGown A (2013) NAD(P)H:Quinone Oxidoreductase 1 Expression in Human Reproductive System and Mitomycin-C Cytotoxicity: A New Chapter for Old Compounds? J Cytol Histol 5: 209. doi:10.4172/2157-7099.1000209

Copyright: © 2013 Zappa F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In our pre-clinical evaluation of RH1, we performed a mapping of this enzyme in normal and tumoral human tissues, with the aim of identifying tumours over-expressing DT-diaphorase and therefore good targets for DTD bio-activated compounds, and also to predict potential toxicities [24,25]. We report our findings concerning the analysis of DTD expression in different components of the human reproductive system.

Materials and Methods

Human tissues

Archival samples of formalin-fixed paraffin-embedded tissues were supplied by the Institute of Pathology of Southern Switzerland, Locarno, Switzerland.

We analysed:
A. 10 biotic samples of normal human testis (contra-lateral normal biopsies from patients undergoing hemi-castration because of testicular cancer).
B. 5 sections of normal human epididymis, that we found when analysing the testicular tumour sections of the above patients.
C. 10 biotic samples of normal human ovary and Fallopian tube.

Methods

We performed an immunohistochemical analysis for the detection of DTD on tissue sections using anti-DTD antibodies.

Antibodies and Reagents: Anti-DTD monoclonal antibody (IgG1)-secreting hybridomas (clones A 180 and B 771) were derived from a BALB-c mouse immunized with purified recombinant human DTD protein. All hybridoma cell lines were grown in spinner flasks in RPMI medium containing 50 units/ml penicillin, 50 µg/ml streptomycin, 1% L-glutamine and 10% fetal bovine serum in 5% CO₂ at 37°C to a concentration of 106 cells/ml. Hybridoma tissue culture supernatants were prepared by centrifugation at 1800 rpm for 10 min and then stored at -80°C.

Prior to use supernatants were centrifuged at 14,000 rpm for 5 minutes. We demonstrated specificity of our proprietary antibody by pre-absorbing it with antigen (human recombinant DTD), and showing that immunohistochemical staining was completely blocked. We also performed a Western analysis on tissue extracts to confirm immunohistochemical staining specificity.

Non-human reactive monoclonal mouse antibodies produced in tissue culture, subclass IgG1, were used as negative control reagent (Mouse IgG1 Negative Control Code No. X0931 DAKO A/S, Denmark).

Immunohistochemical method: Immunohistochemistry was performed on tissue sections (3µm) cut from archival paraffin blocks. Sections were de-paraffinized in xylene and rehydrated through graded alcohol to running water, then placed in citrate buffer pH 6.0 and microwaved for two 3-min cycles. Endogenous peroxidase activity was blocked by adding Peroxidase Blocking Agent (DAKO En Vision Kit, Carpinteria, CA 93013 USA). Non-specific binding was blocked by adding 20% normal rabbit serum. Serial sections of each tissue sample were then incubated with either anti-DTD or control antibodies for 30 minutes at room temperature. The secondary antibody was added for 30 minutes (DAKOKIT, labelled Polymer HRP anti-mouse: peroxidase labelled polymer conjugated to goat anti-mouse immunoglobulins). Immunodetection was performed using a substrate-chromogen solution (DAKOKIT, hydrogend peroxide and 3,3'-diaminobenzidine chromogen). Slides were counterstained with haematoxylin, dehydrated through graded alcohols, mounted and photographed.

Scoring of DTD immunostaining: The intensity of immunostaining of DTD (brown staining) was visually scored as 0 (negative), +1 (very weak), +2 (weak), +3 (strong), +4 (very intense) as previously reported for human lung cancers [26].

Results

All samples analysed were suitable for immunohistochemical analysis of DTD expression. There was no immunostaining in control sections when non-specific antibodies were used.

Immunohistochemical analysis of DTD in human normal testis.

Seminiferous tubules and Sertoli cells

There was no DTD expression (score 0) in any of the samples analysed (Figures 1 and 2). A normal spermatogenesis was present in 9 of 10 samples.

Testicular stroma

There was a very intense expression of DTD in the interstitial cells of the testis (Leydig's cells, score +4, Figures 1 and 2) of all samples.

Figure 1: Immunohistochemical detection of DTD (brown staining) in human testis (low magnification). ST= seminiferous tubules, L= Leydig’s cells.

Figure 2: Immunohistochemical detection of DTD (brown staining) in human testis (high magnification). Score +4 limited to interstitial Leydig’s cells (L), score 0 for seminiferous tubules (ST).
analysed. A strong to very intense (score +3/+4) immunostaining was also found in the endothelial lining of stromal vessels, but not in the connective tissue (score 0).

**Immunohistochemical analysis of DTD in human normal ductuli efferentes and epididymis**

**Epithelial lining**

There was a very intense (score +4) immunostaining in the columnar ciliated epithelial cells of ductuli efferentes (Figures 3 and 4), and a strong (score +3) immunostaining for DTD in the pseudostratified columnar epithelium of the epididymis in cells showing long microvilli (Figure 5).

**Stroma**

There was no or very weak staining for DTD in epididymal and ductuli efferentes stroma.

**Immunohistochemical analysis of DTD in human normal ovary and Fallopian Tube**

**Normal ovary**

We found a weak (score +2) immunostaining for DTD in the mesothelial lining on the surface of the ovary. The connective tissue stroma did not stain for DTD (score 0).

**Fallopian tube**

The Fallopian tube epithelium consists of a single layer of columnar cells of two types, ciliated and non-ciliated. The non-ciliated cells showed no staining for DTD (score 0), but the ciliated cells showed a very intense immunostaining (score +4, Figure 6). The Fallopian tube connective tissue stroma did not stain (score 0).

**Discussion**

Human male infertility secondary to treatment with cytotoxic chemotherapy has been widely described and is almost entirely a function of damage to the seminiferous tubule germinal epithelium [27], revealed by sperm count fall and follicle-stimulating hormone (FSH) increase, and histologically confirmed. Alkylating agents such as busulfan, chlorambucil, cyclophosphamide or procarbazine appear to be the ones most toxic to the germinal epithelium [28-31]. There is very little evidence of Leydig's cell insufficiency after cytotoxic chemotherapy.
Previous studies propose “biological” evidence of Leydig's cell insufficiency as defined by an elevation of luteinizing hormone (LH) levels. No histological demonstration has as yet been reported. Moreover, these studies mainly concern patients treated with alkylating agents for Hodgkin's disease, and are retrospective. Pre-treatment values of gonadal function (testosterone, LH, FSH serum levels) are not available. It is known that Hodgkin's disease is associated with varying degrees of pre-treatment gonadal dysfunction and infertility [36-38]; it is hazardous to postulate Leydig's cell insufficiency in patients with Hodgkin's disease without knowledge of their pre-treatment gonadal function. A recent study showed no relevant evidence of Leydig's cell dysfunction [39]. Gonadal dysfunction after treatment for testicular germ cell cancer has also been widely investigated [40,41], but again this cancer is known to be associated before orchidectomy with spermatogenetic and Leydig's cell dysfunction [42], and the specific role of chemotherapy is therefore difficult to assess.

Our study shows that DT-diaphorase is strongly expressed in various components of the human normal reproductive system, namely, in the interstitial Leydig's cells of the testis that secrete the male sex hormone testosterone and are responsible for the development of male secondary sexual characteristics and essential for the continued function of the seminiferous epithelium where spermatogenesis occurs, as well as in the epithelium of the epididymis, and that of the Fallopian tube that permits the migration of the ovum down the tube by a current of fluid secreted by the non-ciliated cells and propelled by the action of the ciliated cells. The physiological significance of DT-diaphorase in these cells probably has to be ascribed to a detoxifying protective action: from analysis of other human tissues we invariably also found an over-expression of this enzyme in two main categories of cells: hormone-producing cells and cells of body surfaces particularly exposed to noxious agents such as bowel mucosa and urinary tract epithelium. Quinone-induced toxicity to both the digestive and urinary systems have been widely described, in contrast to the scarcity of clinical evidence of such a toxicity on the human reproductive system. This could be explained by the fact that symptoms of testosterone deficiency such as fatigue, depression, loss of libido, impotence or anxiety, can be very aspecific [43]. Furthermore, Leydig's cells are among the most slowly dividing cells in the body, and because of this they may be relatively resistant to DNA-crosslinking agents. However, it is important that this potential toxicity be recognized, because this would render possible a more specific therapeutic approach to symptomatic patients, for instance, by testosterone replacement [44,45]. If further investigations confirm these observations, patients should benefit from pre-treatment counselling concerning their reproductive function, with respect to the chance for recovery of spermatogenesis, fertility, semen cryopreservation, and the possibility of their need for androgen replacement.

Surprisingly, although drugs such as mitomycin C have been in use for years no studies have focused on their effects on fertility and sexual function. A prospective evaluation of gonadal function in patients undergoing anti-cancer treatment with quinones, with serial screenings of testosterone, LH and FSH serum levels, is necessary to assess the magnitude of the problem. Patients who have been treated with these drugs and in whom symptoms potentially related to Leydig's cell dysfunction are seen should also be evaluated for sex hormone function, and this possible mechanism of toxicity should be taken into account in investigations of infertility in men or women after treatment with quinones.

References
1. Gilman A, Phillips FS (1946) The biological actions and therapeutic applications of the chloroethyl amines and sulfides. Science 103: 409-415.
2. Sieber SM, Adamson RH (1975) Toxicity of antineoplastic agents in man: chromosomal aberrations, antifertility effects, congenital malformations and carcinogenic potential. Adv Cancer Res 22: 57-155.
3. Workman P, Stratford IJ (1993) The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev 12: 73-82.
4. Ross D, Beatt H, Traver RD, Siegel D, Phillips RM, et al. (1994) Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies. Oncol Res 6: 493-500.
5. Beatt HD, Murphy AM, Siegel D, Hargraves RH, Butler J, et al. (1995) NAD(P)H: quinone oxidoreductase (DT-diaphorase) as a target for bioreductive anti-tumour quinones; quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol Pharmacol 48: 499-504.
6. Mikami K, Naito M, Tomida A, Yamada M, Sirakusa T, et al. (1996) DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines. Cancer Res 56: 2823-2826.
7. Crestel T, Jaiswal AK (1991) High levels of expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin. Biochem Pharmacol 42: 1021-1027.
8. Belinsky M, Jaiswal AK (1993) NAD(P)H:quinone oxidoreductase 1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev 12: 103-117.
9. Winski SL, Hargraves RH, Butler J, Ross D (1998) A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent. Clin Cancer Res 4: 3083-3088.
10. Gibson NW, Hartley JA, Butler J, Siegel D, Ross D (1992) Relationship between DT-diaphorase-mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity. Mol Pharmacol 42: 531-536.
11. Lee CS, Hartley JA, Berardini MD, Butler J, Siegel D, et al. (1992) Alteration in DNA cross-linking and sequence selectivity of a series of aziridinylbenzoquinones after enzymatic reduction by DT-diaphorase. Biochemistry 31: 3019-3025.
12. Malkinson AM, Siegel D, Forrest GL, Gazdar AF, Oie HK, et al. (1992) Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin C. Cancer Res 52: 4752-4757.
13. Berardini MD, Souhali RL, Lee CS, Gibson NW, Butler J, et al. (1993) Two structurally related diazidinybenzoquinones preferentially cross-link DNA at different sites upon reduction with DT-diaphorase. Biochemistry 32: 3306-3312.
14. Fourie J, Oleschuk CJ, Guziec F Jr, Guziec L, Fiterman DJ, et al. (2002) The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase. Cancer Chemother Pharmacol 49: 101-110.
15. Ross D, Siegel D (2004) NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol 382: 115-144.
16. Ward TH, Danson S, McGown AT, Ranson M, Coe NA, et al. (2005) Preclinical evaluation of the pharmacodynamic properties of 2,5-diazidiny-3-hydroxymethyl-6-methyl-1,4-benzoquinone. Clin Cancer Res 11: 2695-2701.
17. Danson SJ, Johnson P, Ward TH, Dawson M, Denneny O, et al. (2011) Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. Ann Oncol 22: 1653-1660.
18. Begleiter A, Leith MK, Curphey TJ, Doherty GP (1997) Induction of DT-diaphorase in cancer chemoprevention and chemotherapy. Oncol Res 9: 371-382.
19. Wang X, Doherty GP, Leith MK, Curphey TJ, Begleiter A (1999) Enhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase. Br J Cancer 80: 1223-1230.

20. Seerarama L, Hedge MW, Sladek NE (1995) Identification of a class 3 aldehyde dehydrogenase in human saliva and increased levels of this enzyme, glutathione S-transferases, and DT-diaphorase in the saliva of subjects who continually ingest large quantities of coffee or broccoli. Clin Cancer Res 1: 1153-1163.

21. Traver RD, Siegel D, Beall HD, Phillips RM, Gibson NW, et al. (1997) Characterization of a polymorphism in NAD(P):H: quinone oxidoreductase (DT-diaphorase). Br J Cancer 75: 69-76.

22. Siegel D, McGuinness SM, Winski SL, Ross D (1999) Genotype-phenotype relationships in studies of a polymorphism in NAD(P):H:quinone oxidoreductase 1. Pharmacogenetics 9: 113-121.

23. Ross D, Traver RD, Siegel D, Kuehl BL, Misra V, et al. (1996) A polymorphism in NAD(P):H:quinone oxidoreductase (NQO1): relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity. Br J Cancer 74: 995-996.

24. Zappa F, Ward T, Butler J, Pedrinis E, McGown A (2001) Overexpression of NAD(P):H:quinone oxidoreductase 1 in human reproductive system. J Histochem Cytochem 49: 1187-1188.

25. Zappa F, Ward T, Pedrinis E, Butler J, McGown A (2003) NAD(P):H: quinone oxidoreductase in human testis. J Histochem Cytochem 51: 297-302.

26. Siegel D, Franklin WA, Ross D (1998) Immunohistochemical detection of NAD(P):H:quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res 4: 2065-2070.

27. Meistrich ML (1993) Effects of chemotherapy and radiotherapy on spermatogenesis. Eur Urol 23: 136-141.

28. SPITZ S (1948) The histological effects of nitrogen mustards on human tumors and tissues. Cancer 1: 383-398.

29. Fairley KF, Barrie JU, Johnson W (1972) Sterility and testicular atrophy related to cyclophosphamide treatment. Lancet 1: 568-569.

30. Chapman RM, Sutcliffe SB, Rees LH, Edwards CR, Malpas JS (1979) Cytological combination chemotherapy and gonadal function. Retrospective study in males. Lancet 1: 285-289.

31. Charak BS, Gupta R, Mandrekar P, Sheth NA, Banavali SD, et al. (1990) Testicular dysfunction after cyclophosphamide-vinristine-procarbazine-prednisolone chemotherapy for advanced Hodgkin’s disease. A long-term follow-up study. Cancer 65: 1903-1906.

32. Chatterjee R, Mills W, Katz M, McGarrigle HH, Goldstone AH (1994) Germ cell failure and Leydig cell insufficiency in post-pubertal males after autologous bone marrow transplantation with BEAM for lymphoma. Bone Marrow Transplant 13: 519-522.

33. Heikens J, Behrendt H, Adriaanse R, Berghout A (1996) Irreversible gonadal damage in male survivors of pediatric Hodgkin’s disease. Cancer 78: 2020-2024.

34. Mackie EJ, Radford M, Shalet SM (1996) Gonadal function following chemotherapy for childhood Hodgkin’s disease. Med Pediatr Oncol 27: 74-78.

35. Howell SJ, Radford JA, Ryder WD, Shalet SM (1999) Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiency. J Clin Oncol 17: 1493-1498.

36. Chapman RM, Sutcliffe SB, Malpas JS (1981) Male gonadal dysfunction in Hodgkin’s disease. A prospective study. JAMA 245: 1323-1328.

37. Marmor D, Elefant E, Dauchez C, Roux C (1986) Semen analysis in Hodgkin’s disease before the onset of treatment. Cancer 57: 1986-1987.

38. Viviani S, Ragni G, Santoro A, Perrotti L, Caccamo E, et al. (1991) Testicular dysfunction in Hodgkin’s disease before and after treatment. Eur J Cancer 27: 1389-1392.

39. Papadakis V, Vlachopapadopoulou E, Van Syckle K, Ganshaw L, Kalmanti M, et al. (1999) Gonadal function in young patients successfully treated for Hodgkin disease. Med Pediatr Oncol 32: 366-372.

40. Stephenson WT, Poirier SM, Rubin L, Einhorn LH (1995) Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin. J Clin Oncol 13: 2278-2280.

41. Petersen PM, Giwercman A, Skakkebaek NE, Rarth M (1998) Gonadal function in men with testicular cancer. Semin Oncol 25: 224-233.

42. Petersen PM, Skakkebaek NE, Vistisen K, Rarth M, Giwercman A (1999) Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. J Clin Oncol 17: 941-947.

43. Burris AS, Banks SM, Carter CS, Davidson JM, Sherins RJ (1992) A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl 13: 297-304.

44. Arver S, Dobs AS, Meikle AW, Allen RP, Sanders SW, et al. (1996) Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J Urol 155: 1604-1608.

45. Wang C, Alexander G, Berman N, Salehian B, Davidson T, et al. (1996) Testosterone replacement therapy improves mood in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab 81: 3578-3583.